vrc-zkadna090-00-vp
Vaccineexperimental
Clinical trial activity
2 trials · 6 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Dec 8, 2016 (NCT02996461)
Timeline
Indications
Mechanism of action
- Zika virusImmunity, active
immunity, active - zika virus
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vrc-zkadna090-00-vp
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03110770 | Phase 2 | Mar 29, 2017 | FHI 360, Leidos, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), PPD, The EMMES Corporation |
| NCT02996461 | Phase 1 | Dec 8, 2016 | National Institute of Allergy and Infectious Diseases (NIAID) |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (6)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 2 | 2 | 2 | 2016 |
| FHI 360 | Academic/Hospital | 1 | 0 | 1 | 2017 |
| Leidos | For profit | 1 | 0 | 1 | 2017 |
| National Institutes of Health (NIH) | Government | 1 | 0 | 1 | 2017 |
| PPD | For profit | 1 | 0 | 1 | 2017 |
| The EMMES Corporation | For profit | 1 | 0 | 1 | 2017 |
6 organizations
Page 1 / 1